Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05738694 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05738694 · ClinicalTrials.gov record · last posted 2026-03-17

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Name: Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma — clinical trial record (NCT05738694)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorZHOU FANGJIAN

Started2023-04-19

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The study included 298 RCC patients who were at high risk for recurrence after nephrectomy (T2G3-4 or T3-4 or N1). They were randomly divided to receive axitinib plus PD-1 + surgery or surgery alone at a ratio of 1:1, so as to determine the efficacy of the neoadjuvant combination of axitinib plus PD-1.

Amendment record 7 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 7 times since 2023-02-12; most recent amendment 2026-03-15. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-05-04

Status change Not Yet Recruiting→Recruitingv3

Trial Details

NCT Number	NCT05738694
Lead Sponsor	ZHOU FANGJIAN Collaborators: Pfizer
Conditions	Renal Cell Carcinoma, Neoadjuvant
Enrollment	298 participants
Start Date	2023-04-19
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-17